Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
CompletedOBSERVATIONAL
Enrollment
45
Participants
Timeline
Start Date
November 30, 2014
Primary Completion Date
December 31, 2017
Study Completion Date
December 31, 2017
Conditions
Parkinson's Disease
Interventions
DRUG
Rasagiline
Trial Locations (1)
14214
University at Buffalo, Buffalo
All Listed Sponsors
lead
State University of New York at Buffalo
OTHER
NCT02278588 - Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease. | Biotech Hunter | Biotech Hunter